

Beauty Care Solutions



Lys'lastine[™]v Elastin enabler

REF A00076

DESCRIPTION

Aqueous *Anethum Graveolens* extract

REGULATORY DATA

INCI Water, Butylene Glycol, Peucedanum Graveolens (Dill) Extract, Xanthan Gum.

Japanese cosmetic denomination Mizu (1370), BG (100040), Inondo ekisu (559894), Kisantangamu (109058).

CAS# 7732-18-5, 107-88-0, 90028-03-8, 11138-66-2. **EINECS#** 231-791-2, 203-529-7, 289-790-8, 234-394-2.

ORIGIN

Dill seed extract.

FORMULATION DATA

Cosmetic properties

- Stimulates LOXL synthesis,
- Renews elastin functionality.

Applications

- Anti-aging face care,
- Body care elasticity rebuilder.

Concentration of use 1 to 2%

Incorporation methodAdd at the end of the formula at temperatures lower than 35°C.

PATENT

Cenizo V, Bouez C, Sommer P, Damour O, Gleyzal C, Andre V, Reymermier C, Perrier E.

Stimulation of the synthesis and of the activity of an isoform of lysyl oxidase-like LOXL for stimulating the formation of elastic fibers. (Germany: 102004028302), (Korea: 100637934), (Canada: pending), (France: pending), (UK: pending), (Japan: pending), (USA: pending).

Elastin and elasticity breakthrough discoveries

(BASF in association with CNRS institute)

Lys'lastine is one of the most advanced concepts launched recently in the cosmetic industry. It relies on several major discoveries on elastin physiology and mechanics. The key element in cutaneous elasticity during aging is LOXL.

Despite the obvious relationship between elastin and skin elasticity, the structure and aging of this protein are in fact poorly known.

In contrast to other skin constituents such as collagen and glycosaminoglycans (GAGs), that decrease with age, elastin accumulates and changes appearance, as can be observed in skin elastosis.

Thanks to a joint project we have conducted with a French research institute (CNRS), we have made major discoveries on ELASTIN: STRUCTURE, FUNCTIONALITY AND AGING.

Elastin is an assembly of microfibrils and tropoelastin (or soluble elastin). The insoluble nature of the assembly is required for its functionality.

Our work, as well as medical research on pathologies involving structural defaults of elastin, has led to the discovery of the key player regulating the assembly of the two elements: LOXL.

While microfibrils and soluble elastin continue to be synthesized throughout life, LOXL dramatically decreases from the age of 18.

Lys'lastine™v has been developed to help renew skin elasticity, through the reinduction of LOXL synthesis.

Lys'lastine™v the elastin enabler

patented by BASF Beauty Care Solutions

After screening 1000 extracts and molecules, we selected an extract of dill. This extract is called Lys'lastine™ v (v for «vegetal»).

We have shown that Lys'lastine $^{\text{TM}}$ v activates the expression of LOXL mRNA (MIMEDERM $^{\text{TM}}$) and the synthesis of LOXL protein (MIMESKIN $^{\text{TM}}$). We also showed that the increased levels of LOXL in the skin causes the assembly of microfibrils and tropoelastin, leading to improved mechanical properties of the reconstructed skin.


These results were confirmed in a clinical study of 50 women.


What types of new efficacies can be expected from an action that affects elastin?


Elastin is responsible for the **elasticity** of the skin and also acts like a ***tent peg*** in the skin, capable of placing it under tension in 3 **dimensions**.

While restoration of elasticity helps the skin to become a more resilient material without leaving marks, the 3D function favors redesigning face architecture. We are not in the area of face lifting or replumping, as is the case with collagen and GAGs. We offer new types of efficacy from simple well-being to high tech face rejuvenation.

Elastin in the skin discovery of major player







New Stories by Simply elastic...




Skin reactivates its own resilience, like a modern textile

+19% elasticity-resilience



- n=21 subjects per product
 * statistically different from placebo (p<0.05)
- Placebo
- Lys'lastine™v

90% women find their skin texture improved



* significant difference in favor of the product (p<0.05)

Clinical study


- Conducted on 50 women between 43 and 56 years old. A 3-month treatment, 2 applications per day.
- 25 women treated with 1% Lys'lastine™v
- 25 women treated with the placebo
- After 56 and 84 days of treatment, biometric, clinical and self-evaluation parameters were determined.

+11% elasticity



** statistically different from placebo (p<0.01)


100% women are satisfied



* significant difference in favor of the product (p<0.05)

Self assessment

95% women find their skin more elastic



* significant difference in favor of the product (p<0.05)

Lys'lastine™v


The face designer



Lys'lastine™v acts like a skin care artist

Face architecture

81% women find their facial architecture improved



* significant difference in favor of our product (p<0.05)

+10% tonicity of the jaw line




** statiscally significant vs. T0 (p<0.01)

Tenses the skin


Placebo

Lys'lastine™v

-13% wrinkle length



n=20 or 21 subjects per product
* statistically different from placebo (p<0.05



EUROPE & SOUTH AMERICA

BASF Beauty Care Solutions France S.A.S. 49, avenue Georges Pompidou 92593 Levallois-Perret Cedex France

Tel: +33 (0) 1.49.64.53.90 Fax: +33 (0) 1.49.64.53.85 bcs-europe@basf.com

NORTH AMERICA

BASF Beauty Care Solutions LLC 545, Fifth Avenue, Suite 1108 New York, NY 10017 U.S.A.

Tel: +1 (212) 450 8280 Fax: +1 (212) 450 8287 bcs-northamerica@basf.com

JAPAN & ASIA-PACIFIC

BASF Japan Ltd. 21F Roppongi Hills Mori Tower, 6-10-1 Roppongi, Minato-ku, Tokyo, 106-6121 JAPAN

Tel: +81 (0) 3-3796-9214 Fax: +81 (0) 3-3796-9299 bcs-asia@basf.com



The Chemical Company

Edition August 4, 2009

Although all statements and information in this publication are believed to be accurate and reliable, they are presented gratis and for guidance only, and risks and liability for results obtained by use of the products or application of the suggestions described are assumed by the user. THERE ARE NO WARRANTIES OF ANY KIND. ALL EXPRESS AND IMPLIED WARRANTIES ARE DISCLAIMED. Statements or suggestions concerning possible use of the products are made without representation or warranty that any such use is free of patent infringement and are not recommendations to infringe any patent. The user should not assume that toxicity data and safety measures are indicated or that other measures may not be required. The claims and supporting data provided in this publication have not been evaluated for compliance with any jurisdiction's regulatory requirements and the results reported may not be generally true under other conditions or in other matrices. Users must evaluate what claims and information are appropriate and comply with a jurisdiction's regulatory requirements. Recipient of this publication agrees to (i) indemnify and hold harmless each entity of the BASF organization for any and all regulatory action arising from recipient's use of any claims or information in this publication, including, but not limited to, use in advertising and finished product label claims, and (ii) not present this publication as evidence of finished product claim substantiation to any regulatory authority.